دورية أكاديمية
Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19.
| العنوان: | Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19. |
|---|---|
| المؤلفون: | Zhu KW; Office of Pharmacovigilance, Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd. Baiyunshan Pharmaceutical General Factory, Guangzhou 510515, China. |
| المصدر: | ACS pharmacology & translational science [ACS Pharmacol Transl Sci] 2023 Aug 04; Vol. 6 (9), pp. 1306-1309. Date of Electronic Publication: 2023 Aug 04 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Chemical Society Country of Publication: United States NLM ID: 101721411 Publication Model: eCollection Cited Medium: Internet ISSN: 2575-9108 (Electronic) Linking ISSN: 25759108 NLM ISO Abbreviation: ACS Pharmacol Transl Sci Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, DC : American Chemical Society, [2018]- |
| مستخلص: | Deuremidevir hydrobromide tablets and simnotrelvir tablets/ritonavir tablets (co-packaged) were approved by the Chinese National Medical Products Administration for the treatment of mild to moderate COVID-19 in January 2023. Both formulations contain small-molecule anti-SARS-CoV-2 agents. Deuremidevir, an oral nucleoside analog, is a broad-spectrum virus replication inhibitor targeting the highly conserved RNA-dependent RNA polymerase. Simnotrelvir-ritonavir is a co-packaged combination drug consisting of simnotrelvir tablets and ritonavir tablets. Simnotrelvir is an oral antiviral agent targeting the 3-chymotrypsin-like protease, which is essential for SARS-CoV-2 viral replication. Previous clinical trials revealed that both deuremidevir and simnotrelvir-ritonavir were effective and well tolerated in the treatment of COVID-19. Competing Interests: The author declares no competing financial interest. (© 2023 American Chemical Society.) |
| References: | N Engl J Med. 2023 Feb 2;388(5):406-417. (PMID: 36577095) Viruses. 2022 Nov 17;14(11):. (PMID: 36423149) Acta Pharmacol Sin. 2022 Dec;43(12):3130-3138. (PMID: 35296780) Front Immunol. 2022 Dec 06;13:1015355. (PMID: 36561747) Cell Res. 2021 Nov;31(11):1212-1214. (PMID: 34584244) J Antimicrob Chemother. 2020 Jul 1;75(7):1772-1777. (PMID: 32361744) Antibiotics (Basel). 2022 Feb 09;11(2):. (PMID: 35203821) Discoveries (Craiova). 2022 Jun 30;10(2):e151. (PMID: 36156901) Lancet Reg Health West Pac. 2023 Jul 11;38:100835. (PMID: 37484496) Int J Pharm. 2022 May 25;620:121739. (PMID: 35421532) Drug Metab Dispos. 2022 May;50(5):576-590. (PMID: 35153195) |
| تواريخ الأحداث: | Date Created: 20230914 Latest Revision: 20230916 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10496140 |
| DOI: | 10.1021/acsptsci.3c00134 |
| PMID: | 37705591 |
| قاعدة البيانات: | MEDLINE |
Find this issue from the American Chemical Society | تدمد: | 2575-9108 |
|---|---|
| DOI: | 10.1021/acsptsci.3c00134 |